What was SRF's revenue in Q4 FY26?

SRF reported revenue of ₹4,615 Cr in Q4 FY26, a +7% change year-over-year.

Did SRF management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

SRF Q4 FY26 Research Workspace: Revenue ₹4,615 Cr (+7%)

Q: What guidance did SRF management give?

Chemicals business growth 15-20% in FY27: Management expects the chemicals segment to grow 15-20% in FY27, driven by HFC volumes, specialty recovery, and new capacities.

Revenue ₹4,615 Cr +7%

EBITDA ₹3,800 Cr +29%

PAT ₹582 Cr +47%

EBITDA Margin 22% +410bps

Duration 62 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

SRF delivered a strong FY26 with revenue of ₹15,787 crore (+7% YoY), EBITDA of ₹3,800 crore (+29% YoY), and PAT of ₹1,835 crore (+47% YoY), driven by record fluoro-chemicals performance and margin expansion. The chemicals business grew 16% to ₹7,779 crore, while performance films and technical textiles showed recovery. Management guided for 15-20% growth in chemicals in FY27, supported by HFC debottlenecking, specialty chemicals recovery, and new capacities (HFO, fluoropolymers, BOPP). Key risks include geopolitical disruptions in the Middle East, forex mark-to-market losses, and pricing pressure in specialty chemicals from Chinese competition.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

!Risks 4 risks

Risk Intelligence

Geopolitical disruption in Middle East

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

HFC capacity post-debottlenecking >65,000 MTPA

+18% vs current

Debottlenecking investment of ₹88 crore to increase HFC capacity beyond 65,000 metric tons per annum.

HFO capacity investment ₹2,300 crore

New investment

New site in Odisha for 20,000 MTPA HFO capacity, backward integration, and electronic grade HF.

R&D expenditure ₹160 crore

Ongoing

Capital and revenue R&D spend in FY26; 40 patents filed, cumulative 521 filed.

Plan capex FY27 ₹2,500 crore

Consistent with growth plans

Aligned with long-term growth priorities including HFO, fluoropolymers, and pharma intermediates.

Fast read

Guidance and risk preview

Top guidance Chemicals business growth 15-20% in FY27

Management expects the chemicals segment to grow 15-20% in FY27, driven by HFC volumes, specialty recovery, and new capacities.

Top risk Geopolitical disruption in Middle East

Sales into the Middle East were impacted in Q4 due to geopolitical tensions, though management rerouted shipments to other markets.